167 related articles for article (PubMed ID: 26921944)
1. Dual-Color Luciferase Complementation for Chemokine Receptor Signaling.
Luker KE; Luker GD
Methods Enzymol; 2016; 570():119-29. PubMed ID: 26921944
[TBL] [Abstract][Full Text] [Related]
2. Imaging ligand-dependent activation of CXCR7.
Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
[TBL] [Abstract][Full Text] [Related]
3. Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.
Luker K; Gupta M; Luker G
Biotechniques; 2009 Jul; 47(1):625-32. PubMed ID: 19594447
[TBL] [Abstract][Full Text] [Related]
4. Split Gaussia luciferase for imaging ligand-receptor binding.
Luker KE; Luker GD
Methods Mol Biol; 2014; 1098():59-69. PubMed ID: 24166368
[TBL] [Abstract][Full Text] [Related]
5. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
6. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions.
Ray P; Lewin SA; Mihalko LA; Lesher-Perez SC; Takayama S; Luker KE; Luker GD
Biochem J; 2012 Mar; 442(2):433-42. PubMed ID: 22142194
[TBL] [Abstract][Full Text] [Related]
7. Imaging CXCR4 signaling with firefly luciferase complementation.
Luker KE; Gupta M; Luker GD
Anal Chem; 2008 Jul; 80(14):5565-73. PubMed ID: 18533683
[TBL] [Abstract][Full Text] [Related]
8. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
[TBL] [Abstract][Full Text] [Related]
9. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
Luker KE; Mihalko LA; Schmidt BT; Lewin SA; Ray P; Shcherbo D; Chudakov DM; Luker GD
Nat Med; 2011 Dec; 18(1):172-7. PubMed ID: 22138753
[TBL] [Abstract][Full Text] [Related]
10. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
12. Imaging chemokine receptor dimerization with firefly luciferase complementation.
Luker KE; Gupta M; Luker GD
FASEB J; 2009 Mar; 23(3):823-34. PubMed ID: 19001056
[TBL] [Abstract][Full Text] [Related]
13. Class A G protein-coupled receptors assemble into functional higher-order hetero-oligomers.
Gao X; Enten GA; DeSantis AJ; Majetschak M
FEBS Lett; 2021 Jul; 595(14):1863-1875. PubMed ID: 34032285
[TBL] [Abstract][Full Text] [Related]
14. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
15. Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging.
Montpas N; St-Onge G; Nama N; Rhainds D; Benredjem B; Girard M; Hickson G; Pons V; Heveker N
J Biol Chem; 2018 Jan; 293(3):893-905. PubMed ID: 29180449
[TBL] [Abstract][Full Text] [Related]
16. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
17. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
18. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.
Szpakowska M; Nevins AM; Meyrath M; Rhainds D; D'huys T; Guité-Vinet F; Dupuis N; Gauthier PA; Counson M; Kleist A; St-Onge G; Hanson J; Schols D; Volkman BF; Heveker N; Chevigné A
Br J Pharmacol; 2018 May; 175(9):1419-1438. PubMed ID: 29272550
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Mediated Protein Tagging with Nanoluciferase to Investigate Native Chemokine Receptor Function and Conformational Changes.
White CW; Caspar B; Vanyai HK; Pfleger KDG; Hill SJ
Cell Chem Biol; 2020 May; 27(5):499-510.e7. PubMed ID: 32053779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]